Sana Biotechnology Non-GAAP EPS of -$0.14 misses by $0.01 (SANA:NASDAQ)

Sana Biotechnology reported Q3 Non-GAAP EPS of -$0.14, missing estimates by $0.01. Cash reserves decreased by $16.7 million to $121.7 million as of September 30, 2026, due to operational expenses.

Original reporting
Published Nov 5, 2026, 10:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SANA
Bearish
high confidence
Mentioned
$SANA
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$SANABearishMed
01

Why it matters

The earnings miss may prompt a short‑term sell‑off, but the cash reduction could signal operational efficiency.

02

Market read

New earnings numbers provide fresh trading signal for SANA and potentially influence peer biotech stocks.

03

What to watch

Cash burn reduction could be viewed positively despite the EPS miss.

Relevance 6/10Novelty 7/10Timing: after-hours

Background

Sana Biotechnology released its Q3 2026 earnings, reporting a slight EPS miss and a decline in cash balances.

Company-level read

Ticker impact

$SANABearishHigh confidence
Context

Q3 2026 non‑GAAP EPS of -$0.14 missed consensus by $0.01, new earnings disclosure.

Expected impact

downward pressure as market prices in the EPS miss

Evidence & confidence

The miss is a fresh primary disclosure; investors typically react negatively to a surprise earnings shortfall.

Market effects

Biotech sector may see modest pullback as earnings miss adds to sector risk sentiment.

U.S. biotech stocks could face slight downside in early pre‑market trading.

Limited; impact confined to U.S. listed biotech investors.

Counterpoint

If the miss is within a narrow range, the stock may rebound on short‑covering.

Key entities

  • Sana Biotechnology

    U.S. listed biotech firm (NASDAQ:SANA).

Related articles

$SANAMed

Wedbush cuts Sana Biotechnology stock price target on model changes

Wedbush reduced its price target for Sana Biotechnology (NASDAQ:SANA) to $10 from $22, maintaining an Outperform rating. The change reflects model adjustments, excluding hidradenitis suppurativa and updating financing assumptions. Sana's shares have fallen 42% over the past year, trading at $2.40. The company reported a narrower-than-expected Q2 loss of $0.13 per share and holds $160.5 million in cash.

$SANAHighAI 8/10

Sana Biotechnology Reports Q3 Profit; Advances Cell Therapy Programs Toward Clinical Trials

Sana Biotechnology (SANA) reported Q3 2026 net income of $20.4M, with R&D expenses rising to $33.9M. The company has $121.7M in cash, expecting a runway into mid-2027. SANA advanced cell therapy programs for type 1 diabetes and non-Hodgkin lymphoma, targeting clinical trials in 2026-2027. UP421 showed long-term survival in type 1 diabetes study. SANA stock is up 1.75% to $2.38.

$SANAHigh

Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates

Sana Biotechnology, Inc. (SANA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates Continued progress toward starting SC451 Phase 1/2 trial in type 1 diabetes Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma Announced follow-on pu

$AVAIMedAI 8/10

Replacing Insulin Cells Works. Keeping The Cells Alive Is the Trick

AVAI Bio, Vertex, and Sana are developing treatments for Type 1 diabetes by replacing insulin-producing beta cells. Vertex's trial showed 10/12 patients stopped using insulin, but all require immunosuppression. Sana's gene-edited cells evaded immune detection. AVAI Bio's joint venture, Insulinova, is testing encapsulated beta cells with Ospedale San Raffaele. No trials or timelines have been announced.

$SANAMed

Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates

Sana Biotechnology, Inc. (SANA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness Continu

$PANWHighAI 9/10

Palo Alto Networks Reports Fiscal First Quarter 2027 Financial Results

Palo Alto Networks Inc (PANW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Palo Alto Networks Reports Fiscal First Quarter 2027 Financial Results SANTA CLARA, Calif., Nov. 18, 2026 — Palo Alto Networks ® (NASDAQ: PANW), the global AI cybersecurity leader, announced today financial results for its fiscal first quarter ended October 31, 2026.